Gastrointestinal bleeding complicating antiplatelet treatment after percutaneous coronary intervention(PCI)

Gastrointestinal bleeding complicating antiplatelet treatment after percutaneous coronary intervention(PCI) - Gastrointestinal bleeding complicating antiplatelet treatment after PCI

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001610

Enrollment

240

Registered

2009-01-05

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients for indicated antiplatelet treatment after percutaneous coronary intervention(PCI)

Interventions

endoscopic findings is normal and no symptom case: they randomly divided into three treatment arms in each of the groups. Each group was randomly assigned to receive 10 mg omeprazole once a day afte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients indicated for antiplatelet treatment(aspirin and clopidogrel) after percutaneous coronary intervention(PCI)

Exclusion criteria

Exclusion criteria: Patients were excluded if patients had been malignant disease, previous upper abdominal surgery, neuropsychiatric disorder, organic brain damage, severe hepato-renal disorder, symptoms suggesting or were pregnant.

Design outcomes

Primary

Measure	Time frame
The current study attempted to compare the efficacy of rabeprazole with omeprazole in patients indicated for antiplatelet treatment after PCI	—

Secondary

Measure	Time frame
upper gastrointestinal bleeding. Gastrointestinal symptom(Gastrointesitinal Symptom Rating Scale).	—

Countries

Japan

Contacts

Public ContactKouichi Sakurai

Graduate School of Medicine Science, Kumamoto University Department of Gastroenterology and Hepatology,

096-373-5150(+81-96-373-5150)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026